
Jun 3, 2025, 14:12
MiNK Therapeutics receives NIAID grant to advance iNKT cell therapy for stem cell transplant patients
MiNK Therapeutics shared on LinkedIn:
“MiNK Therapeutics has been awarded a NIAID grant to advance its allogeneic iNKT cell therapy for patients undergoing stem cell transplant, with the goal of reducing complications such as GvHD.
This non-dilutive funding supports collaborative research with the University of Wisconsin.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 3, 2025, 08:06
Jul 3, 2025, 07:56
Jul 3, 2025, 07:36
Jul 3, 2025, 07:35
Jul 3, 2025, 07:28